Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Edderd who wrote (19493)	3/9/1999 8:17:00 PM
From: wvalx	Read Replies (1) \| Respond to of 23519

Two points about the "clit cream" (sorry LG just using VLAD's words) patent and possible products: - It's funny to hear investors (?) bemoan the fact that the product is 2 years away. Geez! Talk about instant gratification. I personally think 2 years is not that far away. Sure I would like them to clear $100 million in sales next week, but I also think that it works in Vivus' favor to be able to plan the launch, partnerships or even to dangle it as a carrot. What ever happened to long term vision? - Secondly, I think it's time Vivus got some political clout to get fast track approval ala Viagra. I would like to see an organization like NOW to use their political clout to twist the Congress/FDA's arm, so they don't lollygag. Hey this is where will see if women's needs are treated as equals to men's. Anybody have contacts in NOW? Also, I'm sure Japanese women would be fired up about it after Viagra had a cakewalk into Japan!

To: Edderd who wrote (19493)	3/11/1999 7:29:00 AM
From: BigKNY3	Read Replies (1) \| Respond to of 23519

Edderd: You may find these links of interest: FDA on the early stages of drug development: fda.gov The 1999 AUA Meeting Abstracts have been published including the first double-blind clinical study of sildenafil in women: Message 8255960 The abstract book has several MUSE studies.... including a positive study of MUSE in patients who were unresponsive or could not tolerate Viagra (#813). "57% of these patients achieved an erection sufficient for sexual intercourse..... Most common side effects were penile pain (13%) and urethral burning (5%)." These ED studies and many more will be presented in Dallas on May 1-6, 1999. BigKNY3